U.S. markets close in 1 hour
  • S&P 500

    3,793.44
    +2.51 (+0.07%)
     
  • Dow 30

    30,359.46
    +43.14 (+0.14%)
     
  • Nasdaq

    11,165.87
    -10.54 (-0.09%)
     
  • Russell 2000

    1,759.21
    -16.56 (-0.93%)
     
  • Crude Oil

    87.72
    +1.20 (+1.39%)
     
  • Gold

    1,725.20
    -5.30 (-0.31%)
     
  • Silver

    20.73
    -0.37 (-1.75%)
     
  • EUR/USD

    0.9895
    -0.0091 (-0.91%)
     
  • 10-Yr Bond

    3.7630
    +0.1460 (+4.04%)
     
  • GBP/USD

    1.1344
    -0.0131 (-1.14%)
     
  • USD/JPY

    144.4700
    +0.2710 (+0.19%)
     
  • BTC-USD

    20,213.61
    +85.46 (+0.42%)
     
  • CMC Crypto 200

    457.86
    -0.55 (-0.12%)
     
  • FTSE 100

    7,052.62
    -33.84 (-0.48%)
     
  • Nikkei 225

    27,120.53
    +128.32 (+0.48%)
     

Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference

·1 min read

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the B. Riley Securities 2022 Virtual Oncology Conference. A corporate presentation is scheduled for Thursday, January 27, 2022 at 4 p.m. ET / 1 p.m. PT.

A live webcast of the presentation will be available from the Investor Relations section of the company website at Events & Presentations - Bellicum with a replay available shortly after the live event.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.

Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
858-356-5932
Robert.uhl@westwicke.com